A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme

NCT01115491

Glioblastoma Multiforme

COMPLETED PHASE2

Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma

NCT00501891

Glioblastoma Multiforme

COMPLETED PHASE2

A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma

NCT01860638

Glioblastoma

COMPLETED PHASE2

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00482495

Multiple Myeloma and Plasma Cell Neoplasm

COMPLETED PHASE2

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

NCT00943826

Glioblastoma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bevacizumab 5 mg/kg

Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.

Group Type EXPERIMENTAL

Bevacizumab

Intervention Type DRUG

Bevacizumab was provided as a concentrate in vials.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bevacizumab

Bevacizumab was provided as a concentrate in vials.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Avastin RO 487-6646

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, 19-75 years of age
* Multiple myeloma.
* Progressive disease after at least 2 lines of prior therapy.

Exclusion Criteria

* Non-secretory myeloma.
* History of malignancy, other than squamous cell cancer, basal cell cancer, or cancer in situ of the cervix within the last 5 years.
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start.
* Clinically significant cardiac disease.

Minimum Eligible Age

19 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No